Earlier this year, AZ fired another shot in bladder cancer when Imfinzi was cleared by the FDA alongside Bacillus ...

The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review ...

AstraZeneca’s $1.5 billion cost-savings drive has started to take a toll on its U.S. workforce. | AstraZeneca’s $1.5 billion cost-savings drive has started to take a toll on its U.S. workforce. The ...

With a positive classification from the DEA paving the way for Orzeyful’s U.S. launch on Thursday, Takeda is charting new ...

With Lantheus in the process of being bought out by fellow radiopharmaceutical player Curium, the company is offloading its ...

Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...

Eli Lilly could soon see two label expansions for Foundayo, it’s oral GLP-1, in swift succession: In September, the drugmaker ...

ImmuniyBio is eyeing a move up the non-muscle invasive bladder cancer (NMIBC) treatment line for its immunotherapy Anktiva. ...

Following a back-and-forth with the Pentagon this year, contracting juggernaut WuXi AppTec appears to have largely evaded its ...

Merck KGaA just secured an FDA approval for its new once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, ...

In a series of regulatory wrist-slaps now made public, the FDA has taken three manufacturers to task over record request ...

Following the blue tidal wave in the midterms that restored Democrats to power in both chambers of Congress, lawmakers on the ...